Compugen Reports Second Quarter 2020 Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Compugen Reports Second Quarter 2020 Results

Compugen (CGEN) Tops Q2 EPS by 2c

July 30, 2020 7:49 AM EDT

Compugen (NASDAQ: CGEN) reported Q2 EPS of ($0.08), $0.02 better than the analyst estimate of ($0.10).

"We have reached an exciting phase of development at Compugen, rapidly advancing the clinical evaluation of our DNAM axis hypothesis, suggesting that PVRIG and TIGIT are two parallel and complementary inhibitory pathways in the axis and that blocking both PVRIG and TIGIT may be required in certain tumor types in order to generate or enhance an anti-tumor immune response. Furthermore, these two pathways intersect with the PD-1 pathway and as such, the simultaneous blockade of the three pathways may synergistically enhance... More